title: [Current status of treatment of chronic hepatitis C and related challenges in the "Pre-DAA Era" in China].
abstract: The condition of chronic hepatitis C is becoming more and more serious in China, and its disease burden and social and economic burdens are growing heavier. Currently, the standard regimen for the treatment of chronic hepatitis C in China is the PR regimen, namely pegylated interferon combined with ribavirin; however, there are still many shortcomings in this regimen. In the world, there is rapid clinical progress in direct-acting antiviral agents (DAAs) for the treatment of hepatitis C, and DAAs will soon be approved and marketed in China, ushering the "DAA Era" of hepatitis C treatment. This article reviews the disease burden of chronic hepatitis C and problems in the standard regimen in clinical treatment and briefly introduces the advantages and challenges of DAAs regimens, in order to provide a reference for the upcoming "DAA Era" of hepatitis C treatment in China.
authors.affiliation: Department of Infectious Diseases, Institute for Viral Hepatitis, the Key Laboratory of Molecular Biology for Infectious Diseases, Chinese Ministry of Education, the Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China.
authors.forename: P
authors.initials: P
authors.lastname: Hu
authors.forename: H
authors.initials: H
authors.lastname: Ren
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D002681:China; D004359:Drug Therapy, Combination; D016174:Hepacivirus / Q000187:drug effects* / Q000302:isolation & purification; D019698:Hepatitis C, Chronic / Q000628:therapy*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D012254:Ribavirin / Q000627:therapeutic use*
chemical_list: D000998:Antiviral Agents; D012254:Ribavirin; D007372:Interferons